Research programme: Huntington's disease therapeutics - FORUM Pharmaceuticals

Drug Profile

Research programme: Huntington's disease therapeutics - FORUM Pharmaceuticals

Alternative Names: EVP-3546; EVPK-0003546

Latest Information Update: 01 Dec 2016

Price : $50

At a glance

  • Originator EnVivo Pharmaceuticals
  • Developer FORUM Pharmaceuticals
  • Class Quinazolines; Small molecules
  • Mechanism of Action NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Huntington's disease

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Huntington's-disease in USA
  • 01 Jun 2016 Discontinued - Preclinical for Huntington's disease in USA (unspecified route)
  • 02 Apr 2014 EnVivo Pharmaceuticals is now called FORUM Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top